Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of YY2201 in Advanced Solid Tumors
NCT06976931Phase 1Not yet recruiting
- Sponsor
- Jiangsu Yayao Biotech
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Drug Delivery Systems, Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of YY2201 in solid tumor (advanced stage), sponsored by Jiangsu Yayao Biotech. Primary endpoints: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) and Incidence of Dose-limiting toxicity (DLT). Planned start May 2025; status: not yet recruiting.
02
Drugs
YY2201
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06976931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976931.